DOT1L inhibition has been explored as a therapeutic target for the treatment of DNMT3A mutant AML, wherein reversed DNMT3Amut induced gene activation and resulted in apoptosis and cell differentiation induction in both in vitro and in vivo AML models (80, 81). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.